Comparison of the outcomes of allogeneic bone marrow transplantation from partially mismatched related donors, matched sibling donors, and matched unrelated donors in Japanese pediatric patients: A single center result

Pediatric Transplantation

Volumn 8, Issue 3, 2004, Pages 260-266

  Nagatoshi, Yoshihisa ^a   Kawano, Yoshifumi ^a   Okamura, Jun ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Bone marrow transplantation; Graft versus host disease; Human leukocyte antigen disparity; Partially mismatched related donor; Pediatric patients

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFANT; JAPAN; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; SURVIVAL RATE;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; INFANT; JAPAN; LIVING DONORS; MALE; OPPORTUNISTIC INFECTIONS; PARENTS; RECURRENCE; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 2942735214     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00161.x     Document Type: Article

References (31)

1. BEATTY PG, CLIFT RA, MICKELSON EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985: 313: 765-771.
2. HENSLEE-DOWNEY PJ, ABHYANKAR SH, PARRISH RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1977: 89: 3864-3872.
3. SZYDLO R, GOLDMAN JM, KLEIN JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1977: 15: 1767-1777.
4. CHAMPLIN RE, PASSWEG JR, ZHANG M-J, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000: 95: 3996-4003.
5. CASPER J, CAMITTA B, TRUITT R, et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995: 85: 2354-2363.
6. DAVIES SM, WAGNER JE, SHU XO, et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997: 15: 557-565.
7. BACIGALUPO A, MORDINI N, PITTO A, et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications. Br J Haematol 1997: 98: 760-766.
8. KAWANO Y, TAKAUE Y, WATANABE A, et al. Partially mismatched pediatric transplants with allogeneic CD34+ blood cells from a related donor. Blood 1998: 92: 3123-3130.
9. BENNETT JM, CATOVSKY D, DANIEL MT, et al. The French-American-British (FAB) Co-operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982: 51: 189-199.
10. BENNETT JM, CATOVSKY D, DANIEL MR, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985: 103: 626-629.
11. FORMAN SJ, O'DONNELL MR, NADEMANEE AP, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987: 70: 587-588.
12. STORB R, DEEG HJ, PEPE M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989: 73: 1729-1734.
13. RATANATHARATHORN V, NASH RA, PRZEPIORKA D, et al. Phase 3 study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998: 92: 2303-2314.
14. DEEG HJ, STORB R, THOMAS ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute non-lymphoblastic leukemia. Blood 1985: 65: 1325-1334,
15. STORB R, DEEG HJ, FAREWELL V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease, Blood 1986: 68: 119-125.
16. GLUCKSBERG H, STORB R, FEFER A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974: 18: 295-304.
17. SCHULMAN HM, SULLIVAN KM, WEIDEN PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980: 69: 204-217.
18. BOECKH M, BOWDEN RA, GOODRICH JM, PETTINGER M, MEYERS JD, Cytomegalovirus antigen detection in peripheral blood leukocyte after allogeneic marrow transplantation. Blood 1992: 80: 1358-1364.
19. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
20. OOJI J, ISEKI T, TAKAHASHI S, et al. A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission. Br J Haematol 2002: 118: 140-143.
21. ROCHA V, CORNISH J, SIEVERS EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001: 97: 2962-2971.
22. BARKER JN, DAVIES SM, DEFOR T, RAMSAY NKC, WEISDORF DJ, WAGNER JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001: 97: 2957-2961.
23. PETERSDORF EW, LONGTON GM, ANASETTI C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995: 86: 1606-1613.
24. SASAZUKI T, JUJI T, MORISHIMA Y, et al., for the Japan Marrow Donor Program. Effect of matching of class I HLA on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998: 339: 1177-1185.
25. MORISHIMA Y, SASAZUKI T, INOKO H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002: 99: 4200-4206.
26. MORISHIMA Y, MORISHIMA Y, TANIMOTO M, et al. The Nagoya Bone Marrow Transplantation Group. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. Blood 1989: 74: 2252-2256.
27. MEYERS JD, FLOURNOY N, THOMAS ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986: 153: 478-488.
28. REED EC, BOWDEN RA, DANDLIKER PS, LILLEBY KE, MEYERS JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Inter Med 1988: 109: 783-788.
29. VAN DER BIJ W, TORENSMA R, VAN SON WJ, ANEMA J, SCHIRM J, TEGZESS AM, THE TH. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988: 25: 179-188.
30. BOECKH M, GOOEY TA, MYERSON D, CUNNINGHAM T, SCOTCH G, BOWDEN RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996: 88: 4063-4071.
31. KANDA Y, CHIBA S, HIRAI H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003: 102: 1541-1547.